Turkish PASTUL questionnaire for measuring upper‑limb skin thickness in systemic sclerosis
Official title: Cultural Adaptation, Validity, and Reliability of the Turkish Version of the Patient Assessment of Skin Thickness in the Upper Limb - PASTUL Questionnaire
Run by Hacettepe University · NCT07182968 · Data updated 2026-11-12
This project will test a Turkish version of the PASTUL questionnaire to see if people with systemic sclerosis can use it to measure their upper‑limb skin thickness.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Hacettepe University Academic / other |
| Locations | 1 site (Çankaya, Ankara) |
| Status | Recruiting |
| Started | August 4, 2025 |
| Main results expected | August 2027 |
| Study ends | August 4, 2027 |
| Registry record updated | September 19, 2025 |
| Trial ID | NCT07182968 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with a diagnosis of scleroderma who are willing and able to complete questionnaires are ideal candidates.
✕Probably not a fit
Patients with advanced organ failure, major cognitive or neurological impairment, active malignancy, or those unwilling/unable to complete questionnaires are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will translate and culturally adapt the PASTUL questionnaire into Turkish using forward–backward translation and pilot feedback. They will enroll adults with scleroderma at Hacettepe University and have participants complete the Turkish PASTUL. The team will examine reliability (internal consistency and test–retest) and validity, including correlation with clinician-measured modified Rodnan Skin Score when available. The aim is to confirm the questionnaire's clarity, reliability, and suitability for routine use in the Turkish patient population.
Why it matters
Potential benefit: If successful, Turkish patients could use a simple self-report tool to monitor skin thickness, supporting remote follow-up and earlier recognition of changes.
How similar studies have gone: The original PASTUL has been validated and shown to correlate with the modified Rodnan Skin Score, but this Turkish cultural adaptation has not previously been validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals diagnosed with scleroderma, * Individuals aged 18 years and older Exclusion Criteria: * Advanced heart/lung/liver/kidney disease, neurological disease, and malignancies * Individuals who are unwilling to participate
Where it's running
-
Hacettepe University
Çankaya, Ankara, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Orkun Tüfekçi, PT, PhD(c)
- Email: orkuntf@gmail.com
- Phone: 5319502648
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Biopsychosocial (BETY) exercise program for children and adults with scleroderma
This project will test whether BETY, a biopsychosocial exercise program, helps children and adults with scleroderma improve physical function and psychosocial well-being.
-
Physical performance and daily function in people with scleroderma
This project will test which questionnaires and simple physical tests best measure physical performance and daily functioning in children and adults with scleroderma.
-
Chewing and swallowing performance in people with scleroderma
This project will see how children and adults with scleroderma chew and swallow and collect biopsychosocial information using questionnaires.
-
Progressive Muscle Relaxation for Fatigue and Breathing in Systemic Sclerosis
Aims to see if progressive muscle relaxation can help reduce fatigue and breathing difficulties and improve lung function in adults with systemic sclerosis.
-
FT839 therapy for autoimmune diseases
This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.
-
ATG-201 in adults with autoimmune diseases
This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.